WallStSmart

AbbVie Inc (ABBV)vsProgressive Corp (PGR)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Progressive Corp generates 43% more annual revenue ($87.64B vs $61.16B). PGR leads profitability with a 12.9% profit margin vs 6.9%. ABBV appears more attractively valued with a PEG of 0.49. PGR earns a higher WallStSmart Score of 67/100 (B-).

ABBV

Buy

63

out of 100

Grade: C+

Growth: 4.0Profit: 8.0Value: 4.7Quality: 5.0
Piotroski: 5/9Altman Z: 0.39

PGR

Strong Buy

67

out of 100

Grade: B-

Growth: 8.0Profit: 7.5Value: 7.3Quality: 5.3
Piotroski: 4/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABBVSignificantly Overvalued (-1190.8%)

Margin of Safety

-1190.8%

Fair Value

$16.05

Current Price

$207.18

$191.13 premium

UndervaluedFair: $16.05Overvalued
PGRUndervalued (+76.9%)

Margin of Safety

+76.9%

Fair Value

$900.43

Current Price

$202.84

$697.59 discount

UndervaluedFair: $900.43Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABBV6 strengths · Avg: 9.7/10
Market CapQuality
$362.83B10/10

Mega-cap, among the largest globally

PEG RatioValuation
0.4910/10

Growing faster than its price suggests

Return on EquityProfitability
62.3%10/10

Every $100 of equity generates 62 in profit

Operating MarginProfitability
34.1%10/10

Strong operational efficiency at 34.1%

Debt/EquityHealth
-21.0610/10

Conservative balance sheet, low leverage

Free Cash FlowQuality
$4.89B8/10

Generating 4.9B in free cash flow

PGR5 strengths · Avg: 9.0/10
P/E RatioValuation
10.7x10/10

Attractively priced relative to earnings

Return on EquityProfitability
40.5%10/10

Every $100 of equity generates 41 in profit

Market CapQuality
$120.67B9/10

Large-cap with strong market position

EPS GrowthGrowth
25.2%8/10

Earnings expanding 25.2% YoY

Free Cash FlowQuality
$3.05B8/10

Generating 3.0B in free cash flow

Areas to Watch

ABBV4 concerns · Avg: 2.3/10
Profit MarginProfitability
6.9%3/10

6.9% margin — thin

P/E RatioValuation
87.0x2/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
-88.7%2/10

Earnings declined 88.7%

Altman Z-ScoreHealth
0.392/10

Distress zone — elevated risk

PGR1 concerns · Avg: 2.0/10
PEG RatioValuation
31.572/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : ABBV

The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. PEG of 0.49 suggests the stock is reasonably priced for its growth.

Bull Case : PGR

The strongest argument for PGR centers on P/E Ratio, Return on Equity, Market Cap. Revenue growth of 12.2% demonstrates continued momentum.

Bear Case : ABBV

The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 87.0x leaves little room for execution misses.

Bear Case : PGR

The primary concerns for PGR are PEG Ratio.

Key Dynamics to Monitor

ABBV carries more volatility with a beta of 0.33 — expect wider price swings.

PGR is growing revenue faster at 12.2% — sustainability is the question.

ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.

Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.

Bottom Line

PGR scores higher overall (67/100 vs 63/100) and 12.2% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

AbbVie Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.

Progressive Corp

FINANCIAL SERVICES · INSURANCE - PROPERTY & CASUALTY · USA

The Progressive Corporation is an American insurance company, one of the largest providers of car insurance in the United States. The company insures motorcycles, boats, RVs, and commercial vehicles and provides home insurance through select companies.

Visit Website →

Want to dig deeper into these stocks?